Canada First to Receive New Treatment Option for Liver Cancer Patients
DC Bead LUMI™ Radiopaque Drug-Eluting Bead Offers Interventional Radiologists in Canada a Next Generation Treatment Option for Liver Cancer Patients
OTTAWA, CANADA: BTG International Canada Inc., a part of global specialist healthcare company BTG (LSE: BTG), today announced the commercial launch of DC Bead LUMI™ in Canada. Today’s launch represents the first market commercialization of DC Bead LUMI™ in the world, with regulatory clearances and launches planned for additional markets worldwide.
BTG International Canada Inc. received Health Canada approval for DC Bead LUMI™ in August, 2016.
DC Bead LUMI™ is the first available radiopaque embolic drug-eluting bead that can be loaded with doxorubicin for the treatment of hepatocellular carcinoma (HCC), the most common type of primary liver cancer1 or with irinotecan for the treatment of malignant colorectal cancer metastasized to the liver (mCRC ).2
Drug-eluting beads are used in trans-arterial chemoembolization (TACE), which is a minimally-invasive liver cancer treatment. Drug-eluting bead TACE combines the deliberate blocking of the blood supply to the tumour and delivery of a local, controlled, sustained dose of chemotherapy directly to the tumour.3
DC Bead LUMI™ is a next generation development of DC Bead®, the market leading drug-eluting embolic bead that has the potential to revolutionize the treatment of liver tumours.2
The unique visibility of DC Bead LUMI™ helps optimize patient treatment by enabling real-time visible confirmation of bead location during and after the embolization procedure. This provides interventional radiologists more control, while at the same time facilitating discovery of regions of under-treatment, allowing precise evaluation of the completeness of tumour treatment and enhanced end-point determination, with long-lasting radiopacity to support follow-up management.4
Canadian Hospital First to Offer Treatment Option
Sunnybrook Health Sciences Centre in Toronto, Canada was the first institution to perform the procedure.
“The LUMI TACE beads really delivered. They were what one hoped for; it was easy to see under fluoroscopy, single shot and cone beam CT,” said Dr. Chris Dey, Staff Vascular/Interventional Radiologist, Sunnybrook Health Sciences Centre and Assistant Professor, Faculty of Medicine, University of Toronto. “You can appreciate actual bead deposition in the liver for the first time, flow patterns much more reliably and make intra-procedural adjustments or determine end points more precisely.”
DC Bead LUMI™ is developed on the same technology platform and to the same high standard as DC Bead®, building upon its market leading clinical performance.
“DC Bead LUMI™ allows for the personalization of liver cancer treatment like never before, providing the vision, precision and assurance that the treatment is getting where it needs to be,” added Frank Maiorino, Director, Marketing at BTG International Canada Inc.
“Being the first country to launch this revolutionary product demonstrates the importance of the Canadian market to BTG worldwide,” concludes Brad Pearson, Director, Commercial Operations at BTG International Canada Inc.
BTG is a growing international specialist healthcare company bringing to market innovative products in specialist areas of medicine to better serve doctors and their patients. We have a portfolio of Interventional Medicine products to advance the treatment of liver tumours, severe blood clots, varicose veins and advanced emphysema, and Specialty Pharmaceuticals that help patients overexposed to certain medications or toxins. Inspired by patient and physician needs, BTG is investing to expand its portfolio to address some of today’s most complex healthcare challenges. To learn more about BTG, please visit: www.btgplc.com.
About BTG Interventional Medicine
BTG Interventional Medicine is part of BTG plc, a growing international specialist healthcare company. As medicine moves from major surgery to minor procedure, from the systemic to the local, no company endeavors to do more than BTG Interventional Medicine to help doctors in their quest to see more, reach further and treat smarter. Our growing portfolio of Interventional Medicine products is designed to advance the treatment of liver tumors, advanced emphysema, severe blood clots, and varicose veins. To learn more about BTG Interventional Medicine, please visit: btg-im.com
For more information contact:
Canadian Media Inquiries:
Eileen Tobey, beSPEAK Communications Inc.
+1416 540 4047
International Media Inquiries:
Chris Sampson, Director of Corporate Communications
+44 (0)20 7575 1595; Mobile: +44 (0)7773 251 178
Investor Relations Inquiries:
Andy Burrows, VP Corporate & Investor Relations
+44 (0)20 7575 1741; Mobile: +44 (0)7990 530 605
2. DC Bead LUMI™ Radiopaque Embolic Drug-Eluting Bead Canadian Instructions for Use V.1
4. Duran et al. Theranostics 6(1) 2016:28-39
Back to press releases